**Theme Symposia For RSSDI-2018**

All the RSSDI members are invited to collect original clinical data as per the following themes which can be presented at the 46th Annual Conference of RSSDI 2018 on 23-25 Nov 2018 at Ahmedabad.

* Prof. MMS Ahuja Symposium - "- Population Specific Characteristics of Diabetes in India."
* Prof. B.B. Tripathi Nutrition symposium -  " Dietary Carbohydrate Consumption in Diabetes Patients and Normal Individuals"

**The last Date for Abstract submission is 31st August 2018.**

**Address of Email of Scientific Chair 2018 -**

Dr Rajeev Chawla
Scientific Chair RSSDI 2018

180 Jai Apartment Sec-9 Rohini,

New Delhi-110085.

Tel: +91-11-27563814,Fax: +91-11-47045282

Mobile: +91-9811799666

Email: scientificrssdi2018@gmail.com

 **RSSDI THERAPEUTIC WHEEL**





**Su – Sulfonyl Urea**

**Su\* - Preferably Glimiperide or Gliclazide**

**SuS – Short acting Sulfonyl ureas**

**I – Insulin**

**Ih – Human Insulins**

**Ia – Insulin Analogues**

**IaS – Short Acting Insulin analogues**

**D – DPP4 inhibitors**

**D\* Dose adjustment for linagliptin teneligliptin and gemigliptin is not required**

**P – Pioglitazone**

**P\* - Pioglitazone if EF > 40%**

**Sg – SGLT2 Inhibitors**

**A – Alphaglucosidase Inhibitors**

**G – GLP Analogues**

**Gl – Glinides**

From Innermost to Outermost : A 🡪 Age = Advancing Age; B 🡪 BMI = Increasing BMI; C 🡪 CKD = Advancing CKD; D 🡪 Duration of Diabetes = Increasing Duration; E 🡪 Established CVD = Low CVD risk to Established CVD Risk; F 🡪 Finance = Adequate to Limited; G 🡪 Glycaemic Status = Worsening glycaemic control; H 🡪 Hypoglycemia = Hypoglycaemia concern

Note: Hydroxychlorquinone has recently been approved by DCGI for the treatment of T2DM as third line therapy;

 SGLT2 inhibitors are recommended in patients with high CV risk